ResMed Company Profile (NYSE:RMD)

About ResMed

ResMed logoResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSE
  • Symbol: RMD
  • CUSIP: 76115210
Key Metrics:
  • Previous Close: $63.59
  • 50 Day Moving Average: $67.40
  • 200 Day Moving Average: $62.03
  • 52-Week Range: C$49.11 - C$70.90
  • Trailing P/E Ratio: 25.54
  • Foreward P/E Ratio: 19.75
  • P/E Growth: 2.13
  • Market Cap: $8.95B
  • Outstanding Shares: 140,699,000
  • Beta: 0.71
  • Net Margins: 18.63%
  • Return on Equity: 23.89%
  • Return on Assets: 14.88%
  • Debt-to-Equity Ratio: 0.52%
  • Current Ratio: 2.22%
  • Quick Ratio: 1.87%
Additional Links:
Companies Related to ResMed:

Analyst Ratings

Consensus Ratings for ResMed (NYSE:RMD) (?)
Ratings Breakdown: 4 Sell Ratings, 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 1.85)
Consensus Price Target: C$57.89 (8.97% downside)

Analysts' Ratings History for ResMed (NYSE:RMD)
DateFirmActionRatingPrice TargetDetails
9/19/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details
9/12/2016Needham & Company LLCReiterated RatingSellView Rating Details
8/29/2016Northland SecuritiesSet Price TargetSell$50.00View Rating Details
8/26/2016Barclays PLCReiterated RatingUnderweight$55.00View Rating Details
8/23/2016Jefferies GroupDowngradeHold -> Underperform$60.00 -> $58.00View Rating Details
7/25/2016Canaccord GenuityReiterated RatingHold$57.00View Rating Details
7/10/2016Bank of America Corp.Reiterated RatingHold$65.00View Rating Details
4/27/2016BMO Capital MarketsReiterated RatingHoldView Rating Details
4/27/2016MacquarieUpgradeUnderperform -> NeutralView Rating Details
4/27/2016Citigroup Inc.UpgradeNeutral -> BuyView Rating Details
4/27/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$65.00 -> $57.00View Rating Details
1/22/2016Credit Suisse Group AGUpgradeNeutral -> OutperformView Rating Details
10/6/2015Deutsche Bank AGUpgradeSell -> Hold$53.00 -> $56.00View Rating Details
9/24/2015Goldman Sachs Group Inc.UpgradeNeutral -> Conviction-BuyView Rating Details
7/31/2015Morgan StanleyUpgradeEqual Weight -> OverweightView Rating Details
10/24/2014William BlairUpgradeMarket Perform -> OutperformView Rating Details
(Data available from 9/27/2014 forward)


Earnings History for ResMed (NYSE:RMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q416$0.74$0.74$512.37 million$518.60 millionViewListenView Earnings Details
4/26/2016Q316$0.69$0.68$455.32 million$453.90 millionViewListenView Earnings Details
1/21/2016Q216$0.66$0.69$445.46 million$454.54 millionViewListenView Earnings Details
10/22/2015Q116$0.59$0.58$406.26 million$411.70 millionViewListenView Earnings Details
7/30/2015Q415$0.65$0.68$436.27 million$453.10 millionViewListenView Earnings Details
4/23/2015Q315$0.65$0.65$425.76 million$422.50 millionViewListenView Earnings Details
1/22/2015Q215$0.62$0.64$408.20 million$423.00 millionViewListenView Earnings Details
10/23/2014Q115$0.58$0.58$375.00 million$380.40 millionViewListenView Earnings Details
7/31/2014Q414$0.66$0.64$433.42 million$415.20 millionViewListenView Earnings Details
4/23/2014Q314$0.64$0.63$401.00 million$397.80 millionViewListenView Earnings Details
1/23/2014Q214$0.63$0.60$398.09 million$384.30 millionViewListenView Earnings Details
10/24/2013Q114$0.58$0.56$372.28 million$357.66 millionViewListenView Earnings Details
8/1/2013Q4 2013$0.62$0.62$410.89 million$414.60 millionViewListenView Earnings Details
4/25/2013Q3 2013$0.58$0.58$386.76 million$383.60 millionViewListenView Earnings Details
1/24/2013Q2 2013$0.51$0.53$363.76 million$376.50 millionViewListenView Earnings Details
10/25/2012$0.46$0.49ViewN/AView Earnings Details
8/2/2012$0.49$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.44ViewN/AView Earnings Details
1/26/2012$0.38$0.42ViewN/AView Earnings Details
10/24/2011$0.35$0.33ViewN/AView Earnings Details
8/4/2011$0.37$0.37ViewN/AView Earnings Details
4/28/2011$0.35$0.35ViewN/AView Earnings Details
1/27/2011$0.36$0.37ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ResMed (NYSE:RMD)
Current Year EPS Consensus Estimate: $2.88 EPS
Next Year EPS Consensus Estimate: $3.22 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.70$0.73$0.72
Q2 20162$0.75$0.75$0.75
Q3 20161$0.68$0.68$0.68
Q4 20163$0.75$0.76$0.75
Q1 20172$0.57$0.64$0.61
Q2 20172$0.64$0.73$0.69
Q3 20172$0.67$0.74$0.71
Q4 20172$0.70$0.81$0.76
(Data provided by Zacks Investment Research)


Current Dividend Information for ResMed (NYSE:RMD)
Annual Dividend:$1.32
Dividend Yield:2.08%
Dividend Growth:50.50% (3 Year Average)
Payout Ratio:54.32% (Based on Trailing 12 Months of Earnings)
45.83% (Based on Current Year Consensus EPS Estimate)
40.99% (Based on Next Year Consensus EPS Estimate)

Dividend History for ResMed (NYSE:RMD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for ResMed (NYSE:RMD)
Insider Ownership Percentage: 2.54%
Institutional Ownership Percentage: 61.07%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2016Michael J. FarrellCEOSell5,975C$64.84C$387,419.00View SEC Filing  
9/6/2016David PendarvisInsiderSell6,000C$67.18C$403,080.00View SEC Filing  
9/6/2016Peter C FarrellDirectorSell20,000C$67.29C$1,345,800.00View SEC Filing  
8/19/2016Gary W PaceDirectorSell36,000C$69.93C$2,517,480.00View SEC Filing  
8/17/2016Ronald R TaylorDirectorBuy2,487C$69.13C$171,926.31View SEC Filing  
8/16/2016Ronald R TaylorDirectorSell23,102C$69.25C$1,599,813.50View SEC Filing  
8/15/2016Michael J. FarrellCEOSell5,975C$70.41C$420,699.75View SEC Filing  
8/11/2016Brett SandercockCFOSell35,000C$70.50C$2,467,500.00View SEC Filing  
8/10/2016Richard SulpizioDirectorSell36,000C$70.15C$2,525,400.00View SEC Filing  
8/8/2016John P WarehamDirectorSell24,390C$70.32C$1,715,104.80View SEC Filing  
8/4/2016Peter C FarrellDirectorSell20,000C$69.16C$1,383,200.00View SEC Filing  
8/3/2016David PendarvisInsiderSell6,000C$68.86C$413,160.00View SEC Filing  
7/15/2016Michael J FarrellCEOSell5,975C$65.03C$388,554.25View SEC Filing  
7/14/2016James HollingsheadInsiderSell2,753C$65.02C$179,000.06View SEC Filing  
7/7/2016Peter C FarrellDirectorSell20,000C$63.62C$1,272,400.00View SEC Filing  
7/5/2016David PendarvisInsiderSell6,000C$63.62C$381,720.00View SEC Filing  
6/15/2016James HollingsheadInsiderSell4,458C$59.40C$264,805.20View SEC Filing  
6/15/2016Michael J FarrellCEOSell5,975C$59.63C$356,289.25View SEC Filing  
6/6/2016Peter C FarrellDirectorSell20,000C$59.82C$1,196,400.00View SEC Filing  
6/3/2016David PendarvisInsiderSell6,000C$59.41C$356,460.00View SEC Filing  
5/16/2016Michael J FarrellCEOSell5,975C$57.64C$344,399.00View SEC Filing  
5/4/2016Peter C FarrellDirectorSell20,000C$55.90C$1,118,000.00View SEC Filing  
5/3/2016David PendarvisInsiderSell6,000C$56.02C$336,120.00View SEC Filing  
4/15/2016Michael J FarrellCEOSell5,975C$59.34C$354,556.50View SEC Filing  
4/4/2016David PendarvisInsiderSell6,000C$58.70C$352,200.00View SEC Filing  
4/4/2016Peter C FarrellDirectorSell20,000C$57.51C$1,150,200.00View SEC Filing  
3/15/2016James HollingsheadInsiderSell4,500C$58.57C$263,565.00View SEC Filing  
3/15/2016Michael J FarrellCEOSell5,975C$58.57C$349,955.75View SEC Filing  
3/11/2016Gary W PaceDirectorSell36,000C$60.00C$2,160,000.00View SEC Filing  
3/4/2016Peter C FarrellDirectorSell20,000C$57.51C$1,150,200.00View SEC Filing  
3/3/2016David PendarvisInsiderSell6,000C$57.26C$343,560.00View SEC Filing  
2/29/2016Anne ReiserInsiderSell1,946C$57.06C$111,038.76View SEC Filing  
2/26/2016Brett SandercockCFOSell30,000C$57.61C$1,728,300.00View SEC Filing  
2/26/2016Richard SulpizioDirectorSell36,000C$57.88C$2,083,680.00View SEC Filing  
2/25/2016Peter C FarrellDirectorSell139,980C$57.31C$8,022,253.80View SEC Filing  
2/16/2016Michael J. FarrellCEOSell5,975C$58.20C$347,745.00View SEC Filing  
2/4/2016Peter C. FarrellDirectorSell20,000C$57.70C$1,154,000.00View SEC Filing  
2/3/2016David PendarvisinsiderSell6,000C$57.43C$344,580.00View SEC Filing  
1/27/2016Franz KozichDirectorBuy60,000C$0.04C$2,100.00
1/15/2016Michael J. FarrellCEOSell5,975C$53.07C$317,093.25View SEC Filing  
1/4/2016David PendarvisinsiderSell6,000C$52.16C$312,960.00View SEC Filing  
1/4/2016Peter C. FarrellDirectorSell20,000C$52.22C$1,044,400.00View SEC Filing  
1/4/2016Robert Andrew DouglasCOOSell6,337C$52.97C$335,670.89View SEC Filing  
12/15/2015James HollingsheadInsiderSell4,500C$55.95C$251,775.00View SEC Filing  
12/3/2015David PendarvisinsiderSell6,000C$59.38C$356,280.00View SEC Filing  
12/1/2015Robert Andrew DouglasCOOSell6,333C$59.77C$378,523.41View SEC Filing  
11/25/2015Warren Russell HawkinsDirectorBuy15,000C$0.06C$825.00
11/24/2015Warren Russell HawkinsDirectorBuy3,000C$0.06C$165.00
11/20/2015Christopher G RobertsDirectorSell12,000C$59.03C$708,360.00View SEC Filing  
11/16/2015Michael J. FarrellCEOSell5,975C$57.03C$340,754.25View SEC Filing  
11/12/2015Donald DarkininsiderSell25,442C$57.72C$1,468,512.24View SEC Filing  
11/2/2015Robert Andrew DouglasCOOSell6,333C$57.60C$364,780.80View SEC Filing  
10/27/2015Anne ReiserinsiderSell3,000C$57.01C$171,030.00View SEC Filing  
10/15/2015Michael J. FarrellCEOSell5,975C$55.35C$330,716.25View SEC Filing  
10/5/2015David PendarvisinsiderSell5,500C$52.47C$288,585.00View SEC Filing  
10/5/2015Robert Andrew DouglasCOOSell6,333C$52.13C$330,139.29View SEC Filing  
10/1/2015Peter C. FarrellChairmanSell27,169C$50.93C$1,383,717.17View SEC Filing  
9/15/2015James HollingsheadInsiderSell4,455C$50.67C$225,734.85View SEC Filing  
9/15/2015Michael J. FarrellCEOSell5,975C$50.89C$304,067.75View SEC Filing  
9/3/2015David PendarvisinsiderSell5,500C$51.78C$284,790.00View SEC Filing  
9/3/2015Robert Andrew DouglasCOOSell6,333C$52.04C$329,569.32View SEC Filing  
9/1/2015Peter C. FarrellChairmanSell36,000C$50.82C$1,829,520.00View SEC Filing  
8/28/2015Anne ReiserinsiderSell6,000C$52.26C$313,560.00View SEC Filing  
8/27/2015Richard SulpizioDirectorSell10,860C$51.83C$562,873.80View SEC Filing  
8/17/2015Michael J FarrellCEOSell5,975C$55.54C$331,851.50View SEC Filing  
7/15/2015Michael J FarrellCEOSell5,975C$57.59C$344,100.25View SEC Filing  
7/6/2015David PendarvisInsiderSell5,500C$55.19C$303,545.00View SEC Filing  
7/1/2015Peter C FarrellChairmanSell36,000C$55.61C$2,001,960.00View SEC Filing  
7/1/2015Robert Andrew DouglasCOOSell6,333C$56.59C$358,384.47View SEC Filing  
6/15/2015Michael J FarrellCEOSell5,975C$57.87C$345,773.25View SEC Filing  
6/3/2015David PendarvisInsiderSell5,500C$59.41C$326,755.00View SEC Filing  
6/1/2015Peter C FarrellChairmanSell36,000C$59.25C$2,133,000.00View SEC Filing  
6/1/2015Robert Andrew DouglasCOOSell6,333C$59.22C$375,040.26View SEC Filing  
5/4/2015David PendarvisInsiderSell5,500C$65.10C$358,050.00View SEC Filing  
4/6/2015David PendarvisInsiderSell5,500C$72.60C$399,300.00View SEC Filing  
4/1/2015Peter C FarrellChairmanSell36,000C$70.70C$2,545,200.00View SEC Filing  
4/1/2015Robert Andrew DouglasCOOSell6,333C$70.67C$447,553.11View SEC Filing  
3/27/2015Warren Russell HawkinsDirectorBuy10,000C$0.09C$900.00
3/26/2015Warren Russell HawkinsDirectorBuy10,000C$0.08C$800.00
3/16/2015Anne ReiserInsiderSell4,000C$69.10C$276,400.00View SEC Filing  
3/16/2015Michael J FarrellCEOSell5,975C$69.10C$412,872.50View SEC Filing  
3/9/2015Anne ReiserInsiderSell3,000C$66.75C$200,250.00View SEC Filing  
3/2/2015Peter C FarrellChairmanSell36,000C$64.64C$2,327,040.00View SEC Filing  
3/2/2015Robert Andrew DouglasCOOSell6,333C$64.39C$407,781.87View SEC Filing  
2/17/2015Anne ReiserInsiderSell5,000C$66.11C$330,550.00View SEC Filing  
2/5/2015David PendarvisInsiderSell5,500C$62.35C$342,925.00View SEC Filing  
2/4/2015John P WarehamDirectorSell36,000C$63.49C$2,285,640.00View SEC Filing  
2/3/2015Brett SandercockCFOSell18,670C$62.82C$1,172,849.40View SEC Filing  
2/3/2015Robert Andrew DouglasCOOSell6,333C$62.35C$394,862.55View SEC Filing  
2/2/2015Peter C FarrellChairmanSell36,000C$61.97C$2,230,920.00View SEC Filing  
1/26/2015Gary W PaceDirectorSell48,000C$66.77C$3,204,960.00View SEC Filing  
1/5/2015David PendarvisInsiderSell5,500C$57.09C$313,995.00View SEC Filing  
1/2/2015Peter C FarrellChairmanSell36,000C$56.99C$2,051,640.00View SEC Filing  
1/2/2015Robert Andrew DouglasCOOSell8,000C$56.99C$455,920.00View SEC Filing  
12/1/2014Peter C FarrellChairmanSell36,000C$53.28C$1,918,080.00View SEC Filing  
12/1/2014Robert Andrew DouglasCOOSell8,000C$52.93C$423,440.00View SEC Filing  
11/18/2014Peter C FarrellChairmanSell36,000C$52.39C$1,886,040.00View SEC Filing  
11/3/2014David PendarvisInsiderSell3,557C$52.00C$184,964.00View SEC Filing  
11/3/2014Robert Andrew DouglasCOOSell8,000C$51.84C$414,720.00View SEC Filing  
10/29/2014Peter C FarrellChairmanSell119,204C$51.84C$6,179,535.36View SEC Filing  
10/3/2014David PendarvisInsiderSell5,000C$49.84C$249,200.00View SEC Filing  
10/1/2014Robert Andrew DouglasCOOSell8,000C$49.11C$392,880.00View SEC Filing  
9/15/2014Michael J FarrellCEOSell3,200C$52.41C$167,712.00View SEC Filing  
9/5/2014Brett SandercockCFOSell10,000C$52.99C$529,900.00View SEC Filing  
9/3/2014Brett SandercockCFOSell10,000C$53.23C$532,300.00View SEC Filing  
9/3/2014David PendarvisInsiderSell5,000C$53.23C$266,150.00View SEC Filing  
8/22/2014Anne ReiserInsiderSell3,000C$53.37C$160,110.00View SEC Filing  
8/4/2014David PendarvisInsiderSell5,000C$49.12C$245,600.00View SEC Filing  
8/1/2014Peter C FarrellDirectorSell25,000C$49.04C$1,226,000.00View SEC Filing  
8/1/2014Robert Andrew DouglasCOOSell8,000C$48.95C$391,600.00View SEC Filing  
7/15/2014Michael J FarrellCEOSell3,200C$49.22C$157,504.00View SEC Filing  
7/3/2014David PendarvisInsiderSell5,000C$50.04C$250,200.00View SEC Filing  
7/1/2014Peter C FarrellDirectorSell25,000C$50.09C$1,252,250.00View SEC Filing  
7/1/2014Robert Andrew DouglasCOOSell8,000C$50.11C$400,880.00View SEC Filing  
6/16/2014Michael J FarrellCEOSell3,200C$53.20C$170,240.00View SEC Filing  
6/3/2014David PendarvisInsiderSell5,000C$49.76C$248,800.00View SEC Filing  
6/2/2014Peter C FarrellDirectorSell25,000C$49.57C$1,239,250.00View SEC Filing  
6/2/2014Robert Andrew DouglasCOOSell8,000C$50.11C$400,880.00View SEC Filing  
5/29/2014Christopher G RobertsDirectorSell25,000C$49.73C$1,243,250.00View SEC Filing  
5/15/2014Michael FarrellCEOSell3,700C$50.54C$186,998.00View SEC Filing  
5/13/2014John WarehamDirectorSell18,000C$51.00C$918,000.00View SEC Filing  
5/8/2014Brett SandercockCFOSell5,000C$50.00C$250,000.00View SEC Filing  
5/6/2014Brett SandercockCFOSell4,290C$50.00C$214,500.00View SEC Filing  
5/1/2014Peter FarrellDirectorSell25,000C$49.80C$1,245,000.00View SEC Filing  
5/1/2014Robert Andrew DouglasCOOSell8,000C$49.75C$398,000.00View SEC Filing  
4/29/2014David PendarvisInsiderSell15,000C$50.01C$750,150.00View SEC Filing  
4/21/2014Peter FarrellDirectorSell75,000C$48.01C$3,600,750.00View SEC Filing  
4/4/2014David PendarvisInsiderSell5,000C$44.95C$224,750.00View SEC Filing  
2/12/2014Brett SandercockCFOSell10,687C$46.00C$491,602.00View SEC Filing  
1/9/2014Peter FarrellDirectorSell25,000C$48.00C$1,200,000.00View SEC Filing  
12/2/2013Robert Andrew DouglasCOOSell8,000C$49.10C$392,800.00View SEC Filing  
11/20/2013Brett SandercockCFOSell15,000C$51.06C$765,900.00View SEC Filing  
11/20/2013James HollingsheadInsiderSell4,000C$51.24C$204,960.00View SEC Filing  
11/12/2013Donald DarkinInsiderSell31,063C$50.04C$1,554,392.52View SEC Filing  
10/29/2013David PendarvisInsiderSell37,744C$50.42C$1,903,052.48View SEC Filing  
10/1/2013Peter C FarrellDirectorSell25,000C$53.21C$1,330,250.00View SEC Filing  
10/1/2013Robert Andrew DouglasCOOSell8,000C$53.20C$425,600.00View SEC Filing  
9/9/2013Gary W PaceDirectorSell12,000C$50.05C$600,600.00View SEC Filing  
9/5/2013Peter C FarrellDirectorSell25,000C$48.00C$1,200,000.00View SEC Filing  
9/3/2013Robert Andrew DouglasCOOSell8,000C$47.51C$380,080.00View SEC Filing  
8/28/2013Michael QuinnDirectorSell48,000C$48.34C$2,320,320.00View SEC Filing  
8/27/2013Brett SandercockCFOSell5,000C$49.00C$245,000.00View SEC Filing  
8/26/2013Christopher RobertsDirectorSell10,000C$49.49C$494,900.00View SEC Filing  
8/1/2013Robert Andrew DouglasCOOSell8,000C$48.57C$388,560.00View SEC Filing  
6/3/2013Robert Andrew DouglasCOOSell8,000C$47.96C$383,680.00View SEC Filing  
5/24/2013Christopher G RobertsDirectorSell20,000C$49.45C$989,000.00View SEC Filing  
5/22/2013John P WarehamDirectorSell18,000C$50.20C$903,600.00View SEC Filing  
5/13/2013Michael A QuinnDirectorSell15,000C$50.94C$764,100.00View SEC Filing  
5/8/2013Brett SandercockCFOSell28,000C$48.97C$1,371,160.00View SEC Filing  
2/4/2013Robert Andrew DouglasCOOSell8,000C$44.14C$353,120.00View SEC Filing  
8/8/2012Michael J FarrellInsiderSell30,000C$35.58C$1,067,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for ResMed (NYSE:RMD)
DateHeadline logoResMed Becomes Oversold (NYSE:RMD) - September 23 at 1:48 PM
News IconUpcoming Earnings Report: ResMed Inc. (NYSE:RMD) - The Voice Registrar (NYSE:RMD) - September 22 at 6:45 PM logoStock Headed in the Right Direction Over the Past Year: ResMed Inc. (NYSE:RMD) (NYSE:RMD) - September 21 at 6:41 PM
News IconResMed Inc. (NYSE:RMD) earnings expectations - The Independent Republic (NYSE:RMD) - September 19 at 7:00 PM logoU.S. trade authorities to probe some imported sleep disorder systems (NYSE:RMD) - September 19 at 7:00 PM
News IconStock Update on Earnings & Estimates for ResMed Inc. (NYSE:RMD) - Frisco Fastball (NYSE:RMD) - September 19 at 11:39 AM
News IconAnalysts Valuations For Two Stocks: Unum Group (NYSE:UNM), ResMed Inc. (NYSE:RMD) - The Voice Registrar (NYSE:RMD) - September 19 at 11:39 AM
News IconHC Stocks Updates! Davita Inc (DVA), ResMed Inc. (NYSE:RMD) - share market updates (press release) (NYSE:RMD) - September 19 at 11:39 AM
News IconEarnings According to Analysts for ResMed Inc. (NYSE:RMD)? - Frisco Fastball (NYSE:RMD) - September 18 at 11:16 AM logoResMed Inc. Common Stock (NYSE:RMD) Trading Down – Insider Trading Activity (NYSE:RMD) - September 17 at 6:34 PM
News IconAnalysts Valuations For Two Stocks: ResMed Inc. (NYSE:RMD), Intersil Corp (NASDAQ:ISIL) - The Voice Registrar (NYSE:RMD) - September 16 at 6:50 PM
News IconVan Hulzen Asset Management LLC Decreased Stake in Resmed ... - Chester News (NYSE:RMD) - September 15 at 10:40 AM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: ResMed Inc. (NYSE:RMD) - Frisco Fastball (NYSE:RMD) - September 14 at 7:13 PM
News IconResMed Inc. (RMD) - Medical Equipment - Deals and Alliances Profile - New Market Study Published (NYSE:RMD) - September 12 at 6:41 PM logoResMed, Inc. breached its 50 day moving average in a Bearish Manner : RMD-US : September 9, 2016 (NYSE:RMD) - September 9 at 11:51 AM logoResMed Inc. (NYSE:RMD) Rating In Focus - Investor Newswire (NYSE:RMD) - September 8 at 6:47 PM logoNew Study Shows Using Non-Invasive Ventilation Therapy to Treat Patients with Chronic Obstructive Pulmonary Disorder (COPD) at Home Significantly Reduces Risk of Re-Hospitalization and Death (NYSE:RMD) - September 6 at 11:49 AM logoETF’s with exposure to ResMed, Inc. : September 6, 2016 (NYSE:RMD) - September 6 at 11:49 AM
News IconCrowd & Street Monitoring ResMed Inc. (NYSE:RMD) Shares - Post News (NYSE:RMD) - August 30 at 7:00 PM
News IconStock Gapping Lower Before the Bell: ResMed Inc. (NYSE:RMD) - Post News (NYSE:RMD) - August 29 at 11:42 AM
News IconResMed Inc. (RMD) Downgraded to Underperform at Jefferies Group (NYSE:RMD) - August 28 at 6:16 PM logoRising Street Value Of ResMed Shares Disconnected From Its Fundamentals (NYSE:RMD) - August 25 at 7:22 PM logoStocks on Trader's Radar: ResMed Inc. (RMD), CVS Health Corporation (CVS), EOG Resources, Inc. (EOG) - iStreetWire (NYSE:RMD) - August 24 at 6:51 PM logoETF’s with exposure to ResMed, Inc. : August 22, 2016 (NYSE:RMD) - August 22 at 7:03 PM logoResMed, Inc. :RMD-US: Earnings Analysis: 2016 By the Numbers : August 22, 2016 (NYSE:RMD) - August 22 at 11:44 AM
News IconActive Momentum Stocks- Chesapeake Energy (NYSE:CHK), ResMed Inc. (NYSE:RMD), The Hain Celestial Group ... - Seneca Globe (NYSE:RMD) - August 19 at 10:05 AM logoResMed : Takes Fisher & Paykel to Court over Patents (NYSE:RMD) - August 17 at 7:32 PM logo5:13 pm ResMed files patent infringement actions against Fisher & Paykel Healthcare in U.S., German and New Zealand courts and in the U.S. International Trade Commission (NYSE:RMD) - August 17 at 7:32 PM logoResMed Takes Fisher & Paykel to Court over Patents (NYSE:RMD) - August 17 at 7:32 PM logoResMed files legal action against Fisher & Paykel Healthcare (NYSE:RMD) - August 17 at 7:32 PM logoWill ResMed Inc. (NYSE:RMD) Keep up With Analyst Expectations? - Investor Newswire (NYSE:RMD) - August 16 at 7:17 PM logoFisher & Paykel Files Patent Infringement Claim Against ResMed (NYSE:RMD) - August 15 at 7:33 PM logoFisher & Paykel Healthcare file Patent Infringement Proceedings against ResMed (NYSE:RMD) - August 15 at 7:33 PM logoRESMED INC Financials (NYSE:RMD) - August 11 at 7:42 PM logoResMed Inc. Common Stock (NYSE:RMD) Trading Down – Insiders Are Selling (NYSE:RMD) - August 10 at 7:38 PM logoLarge Inflow of Money Detected in ResMed (NYSE:RMD) - August 10 at 10:16 AM
News IconCochlear Limited could be a bargain on today’s share price weakness (NYSE:RMD) - August 9 at 10:23 AM logoETF’s with exposure to ResMed, Inc. : August 8, 2016 (NYSE:RMD) - August 8 at 7:24 PM logoResMed, Inc. :RMD-US: Earnings Analysis: Q4, 2016 By the Numbers : August 5, 2016 (NYSE:RMD) - August 5 at 7:24 PM logoRESMED INC Files SEC form 10-K, Annual Report (NYSE:RMD) - August 5 at 7:24 PM logoResMed, Inc. :RMD-AU: Earnings Analysis: 2016 By the Numbers : August 4, 2016 (NYSE:RMD) - August 4 at 10:21 AM logoResMed, Inc. :RMD-AU: Earnings Analysis: Q4, 2016 By the Numbers : August 4, 2016 (NYSE:RMD) - August 4 at 10:21 AM logoNotable Analysts Assessment of Stocks: CytRx Corporation (NASDAQ:CYTR) , ResMed Inc. (NYSE:RMD) - Street Updates (NYSE:RMD) - August 2 at 7:30 PM logoResmed Inc. (RMD) Jumped To A New High After Q4 Earnings Met Expectations (NYSE:RMD) - August 1 at 11:49 AM
News IconResMed increases dividends off back of Q4 results (NYSE:RMD) - July 29 at 7:19 PM
News IconResMed shares lift on solid Q4 posting (NYSE:RMD) - July 29 at 7:19 PM logoResMed : Firms and Funds Increasing Their Stake in ResMed Inc. (NYSE:RMD) - July 29 at 7:19 PM logoEdited Transcript of RMD earnings conference call or presentation 28-Jul-16 8:30pm GMT (NYSE:RMD) - July 29 at 11:11 AM logoResMed (RMD) Q4 Earnings in Line, Revenues Top Estimates (NYSE:RMD) - July 29 at 10:14 AM
News IconFrontline Trades in Focus- NetSuite Inc. (NYSE:N), ResMed (NYSE:RMD), Argos Therapeutics, Inc. (NASDAQ:ARGS) - Seneca Globe (NYSE:RMD) - July 29 at 10:12 AM


ResMed (NYSE:RMD) Chart for Tuesday, September, 27, 2016

Last Updated on 9/27/2016 by Staff